Trials.These are the current enrolling trials managed by Lumi Research. If you think you qualify for any of the trials, please contact us for more information.
|
|
|
Prophylactic Trials
Early Detection / Cancer Screening |
Colorectal Cancer |
RXC004 +/- Nivolumab (RedX)
This is a Phase II, open label, multicentre, multi-arm, study to evaluate the preliminary efficacy and safety of RXC004 as monotherapy and in combination with nivolumab in patients with Ring finger protein 43 (RNF43) or R-spondin (RSPO) aberrated, microsatellite stable (MSS), colorectal cancer (CRC), that have progressed following current standard of care treatment.
Targeted therapy (WO42758/INTRINSIC)
This open-label, exploratory study is designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or combinations, in participants with metastatic colorectal cancer (mCRC) whose tumors are biomarker positive as per treatment arm-specific definition. Eligible participants with mCRC will be enrolled into specific treatment arms based on their biomarker assay results.
Myeloma |
Breast Cancer |
Datopotamab Deruxtecan (Dato-DXd) vs Standard of Care Chemo (TROPION-Breast02)
This is a Phase III randomized study of Dato-DXd vs chemotherapy (provider's choice) in patients who are not candidates for PD-1/PD-L1 Inhibitor Therapy in First-line locally recurrent inoperable or metastatic triple-negative breast cancer.
Giderestrant + Everolimus vs Exemestate + Everolimus (ML43171/evERA)
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With Exemestane Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
Inavolisib / Alpelisib in combination with Fulvestrant (WO43919/INAVO121)
This is a Phase III, multicenter, randomized, open-label, global study designed to evaluate the efficacy and safety of inavolisib plus fulvestrant compared with alpelisib plus fulvestrant in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2) -negative, PIK3CA-mutated, locally advanced (LA) or metastatic breast cancer (mBC), who progressed during or after cyclin dependent kinase 4/6i (CDK4/6i)-based therapy.
Inavolisib in combination with Phesgo (WO44263/INAVO122)
This study evaluates the efficacy and safety of inavolisib in combination with Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for subcutaneous use) compared with placebo in combination with Phesgo, as maintenance therapy, after induction therapy in participants with previously untreated HER2-positive advanced breast cancer (ABC).
Solid Tumor Cancer |
First in human TPX-005 (TRIDENT-1)
A Phase 1/2 first in human study of the safety, tolerability, pharmacokinetics and anti-tumor activity of TPX-005 in patients with advanced solid tumors with ALK, ROS1, or NTRK1-3 rearrangements.
Adagrasib (849-001/Krystal 1)
This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.
MTAP + PRMT5 mono and in combination w/ docetaxel (AMG 193 20210023)
A phase 1/2 study that evaluates the safety, tolerability and maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of AMG 193 alone or in combination with docetaxel for patients with MTAP null solid tumors.
Leukemia |
Chronic Myelogenous Leukemia (CML) - Asciminib vs Nilotinib (CABL001J12302/ASC4START)
A phase Ill, multi-center, open-label, randomized study of oral asciminib versus Investigator selected TKI in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase. The study is designed to compare the tolerability of asciminib versus nilotinib for the treatment of newly diagnosed, previously untreated patients with Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP).
Chronic Lymphocytic Leukemia (CLL) - BGB-11417 + Zanubrutinib vs Venetoclax + Obinutuzumab
A phase Ill, open-label, randomized study of BGB-11417 (Sonrotoclax) plus Zanubrutinib compared with Venetoclax plus Obinutuzumab in patients with previously untreated, CLL or small lymphocytic lymphoma given in first line setting.
Lung Cancer |
Neoadjuvant/Adjuvant biomarker selected basket study (NAUTIKA1)
This is a phase III, multi center, neoadjuvant or adjuvant study of multiple therapies in biomarker-selected patients with resectable staged IB-III Non-small cell lung cancer (NSCLC).
Serplulimab with chemotherapy vs Atezolizumab with chemotherapy (ASTRIDE)
This is a phase III, randomized (1:1) trial comparing Serplulimab with chemotherapy (carboplatin+etoposide) vs atezolizumab with chemotherapy for previously untreated patients with extensive stage small cell lung cancer (ES-SCLC).
Serplulimab with chemotherapy plus concurrent radiotherapy (ASTRUM-LC01)
This is a phase III, double-blind, randomized, multi-center trial comparing the clinical efficacy and safety of Serplulimab with chemotherapy and radiotherapy vs chemotherapy (carboplatin/cisplatin+etoposide) and radiotherapy in patients with with limited stage small cell lung cancer (LS-SCLC).
Datopotomab Deruxtecan (Data-DXd) with durvalumab and carboplatin vs pembrolizumab plus chemo (AVANZAR)
This is a phase III, randomized, open-label multi-center global study comparing the efficacy and safety of Dataopotamab Deruxtecan (Dato-DXd) in combination with durvalumab and carboplatin vs pembrolizumab in combination with histologically-specific platinum-based chemotherapy as a FIRST LINE treatment for adults with late stage/metastatic non small cell lung cancer (LS/Metastatic NSCLC) without genomic alterations.
Questions?
|
Clinical trials offer patients another option to receive treatment and often times, may come free of charge. If you think that you may be qualified, may be interested in participating and have any of the diseases listed above, the study team is available to answer any questions you have.
Contact the team today and a clinical research coordinator will respond to your inquiry within 24 hours. |
|
Completed Studies
Our Patients Come FirstWe tirelessly work with our sites to open trials as quickly as possible. This helps bring more trials to a local care team for patients who are unable to go to a major institution or remote place.
|
We Promise You the BestOur team is dedicated to helping everyone in the process of clinical trials. We start with the patient in mind and work with everyone all the way to the sponsor of the trial. This way we have a complete picture of everyone's needs .
|
